GlassScriptPhysician profile
Thomas Houston Clark
NPI 1295741114
$332,174.67
in general payments reported to CMS, 2019-2025
34 companies · $55K in 2025
The $55K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50K · 2020: $31K · 2021: $14K · 2022: $66K · 2023: $56K · 2024: $60K · 2025: $55K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $125K · Travel and Lodging: $18K · Consulting Fee: $14K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $7,069 · Food and Beverage: $6,924 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $125,043.00 |
| Travel and Lodging | $18,068.60 |
| Consulting Fee | $14,207.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $7,068.75 |
| Food and Beverage | $6,924.12 |
| Education | $117.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $254,560.33 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44,621.67 | 2019-2025 | Jardiance, Synjardy |
| Abbott Laboratories | $16,873.13 | 2021-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $7,084.25 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Corcept Therapeutics | $4,424.31 | 2021-2025 | Korlym |
| Eli Lilly and Company | $2,860.32 | 2023 | |
| Insulet Corporation | $297.26 | 2020-2025 | Omnipod, Omnipod |
| Sanofi-Aventis U.S. LLC | $195.19 | 2024-2025 | |
| Renalytix Ai, INC. | $188.02 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Medtronic, INC. | $161.49 | 2025 | Minimed 780g, Inceptiv |
| Dexcom, INC. | $108.43 | 2024-2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $101.51 | 2021 | |
| Janssen Pharmaceuticals, INC | $74.94 | 2019 | |
| Pfizer INC. | $61.18 | 2024-2025 | |
| Amarin Pharma, INC. | $59.25 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $50.27 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Beta Bionics, INC. | $49.76 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Bayer Healthcare Pharmaceuticals INC. | $47.72 | 2024-2025 | |
| Amgen INC. | $47.71 | 2025 | Evenity |
| Averitas Pharma INC. | $37.08 | 2025 | Qutenza |
| Madrigal Pharmaceuticals | $31.50 | 2024 | Resmetirom |
| Tandem Diabetes Care, INC. | $27.96 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $25.64 | 2024 | |
| Novartis Pharmaceuticals Corporation | $19.72 | 2024 | |
| Chiesi USA, INC. | $19.36 | 2025 | Cleviprex |
| Merck Sharp & Dohme LLC | $18.69 | 2024 | Vaxelis, Gardasil, Gardasil 9 |
| Astrazeneca Pharmaceuticals LP | $18.60 | 2025 | Farxiga |
| Ascensia Diabetes Care US INC. | $17.57 | 2025 | |
| Becton, Dickinson and Company | $17.27 | 2024 | Bd Surepath Collection Vial |
| Boston Scientific Corporation | $16.75 | 2025 | Wavewriter Alpha Prime 16 |
| Phathom Pharmaceuticals, INC. | $16.60 | 2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.22 | 2025 | Caplyta |
| Organon LLC | $13.74 | 2024 | |
| Acacia Pharma INC | $12.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.